Our attorneys have filed a mass tort lawsuit on behalf of sufferers who took the blood thinner Xarelto (rivaroxaban) and suffered significant bleeding events. Pharmaceutical organizations, such as the makers of Xarelto, possess a duty to ensure that their drugs are reasonably secure for use – and failure to do so may possibly be grounds for compensation. Our lawyers are operating hard to obtain these hurt by the drug the compensation they may be entitled to.
While bleeding is a typical complication connected with anticoagulants, it has been alleged that Xarelto is much more dangerous than standard blood thinners due to the fact no antidote exists to reverse its blood-thinning effects. This means that, in the occasion of an emergency, patients may possibly be at threat for irreversible bleeding problems, including life-threatening internal and gastrointestinal hemorrhaging.
If you or possibly a loved one particular suffered a severe bleeding event following taking Xarelto, you might have legal recourse. For a lot more information, make contact with us right now to possess your case reviewed, free of charge of charge.
Compensation Possibilities
xarelto-compensation-photoThe plaintiffs in these lawsuits are searching for compensation from Bayer and Janssen for past and future medical bills, lost wages, discomfort and suffering and, in cases of death, funeral costs. Additionally, they are seeking punitive damages, which are usually awarded to punish the defendant and deter other businesses from acting similarly.
Why Are Lawsuits Becoming Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is dangerous and defective. The plaintiffs claim that, unlike classic anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Since of this, the lawsuits claim, doctors have no effective implies of stopping Xarelto users from bleeding in the event of an emergency. Plaintiffs within the lawsuits allege severe and fatal injuries, which includes cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a secure anticoagulant option.
Doctors and health-related staff were not properly made aware of methods to stabilize and treat a Xarelto user in the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to significant bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing hazardous clotting.
Visit this page for more details on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys in the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.